Synta Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Synta Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#714 of 15,751 sponsors by registered trial count).
Synta Pharmaceuticals: 21 sponsored US clinical trials, none currently recruiting.
Synta Pharmaceuticals sponsors 21 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 18 completed. 2 of these trials are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 1 trials.
Top-decile sponsor footprint
Synta Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#714 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Indexed trials (enrollment closed)
21 total, page 1 of 1
A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
NCT01798485
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
NCT01677455
A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT01562015
Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer
NCT01348126
A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors
NCT01183364
A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)
NCT01039519
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
NCT01031225
A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia
NCT00964873
STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders
NCT00858572
A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer
NCT00808418
Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors
NCT00687934
Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma
NCT00522834
Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease
NCT00234741
Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease
NCT00138840
A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas
NCT00087997
A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors
NCT00276913
STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma
NCT00084214
STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
NCT00088088
STA-5326 in Crohn's Disease Patients
NCT00088062
STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors
NCT00088101
STA-4783 and Paclitaxel for Treatment of Solid Tumors
NCT00088114
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 8 |
| Phase 3 | 2 |
Therapeutic Areas
How the Synta Pharmaceuticals early-phase archive is shaped
21 indexed studies, none listed as recruiting (0% open); 18 completed (86%).
Phase mix: 2 late (III/IV) vs 19 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.